Company Diamyd Medical AB

Equities

DMYD B

SE0005162880

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for Diamyd Medical AB

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs

Delayed Nasdaq Stockholm Other stock markets 06:23:54 18/06/2024 pm IST			5-day change	1st Jan Change
13.74 ^SEK	-2.28%		-2.14%	+109.13%

16/05	Diamyd Medical AB Updates on the Registrational Phase 3 Trial	CI
18/04	Diamyd Medical Raises SEK57 Million in Rights Issue	MT

Diamyd Medical AB is a Sweden-based diabetes company. It is active in the field of pharmaceutical development and investments in stem cell and medical technology. The Company develops the diabetes vaccine, Diamyd, with the active glutamic acid decarboxylase (GAD) ingredient for the treatment and prevention of autoimmune diabetes. The vaccine is intended for the treatment of children and adolescents with recent-onset type one diabetes, as well as those at high risk of developing the disease.

Number of employees: 26

SEK in Million	2022	Weight	2023	Weight	Delta
Pharmaceutical Products 100.0 %	0	100.0 %	1	100.0 %	+20.26%

SEK in Million	2022	Weight	2023	Weight	Delta
Sweden 100.0 %	0	100.0 %	1	100.0 %	+20.26%

Managers	Title	Age	Since
Ulf Hannelius CEO	Chief Executive Officer	49	10/16/10
Anders Essen-Möller FOU	Founder	83	01/96/01
Anna Styrud DFI	Director of Finance/CFO	63	01/10/01
Christoph Nowak CTO	Chief Tech/Sci/R&D Officer	38	01/21/01
Anton Lindqvist CTO	Chief Tech/Sci/R&D Officer	44	01/13/01
Martina Widman COO	Chief Operating Officer	43	01/16/01
Markus Jerling CTO	Chief Tech/Sci/R&D Officer	72	-

Members of the board	Title	Age	Since
Anders Essen-Möller FOU	Founder	83	01/96/01
Erik Kjellsson Nerpin BRD	Director/Board Member	63	01/12/01
Karin Hehenberger BRD	Director/Board Member	52	28/21/28
Carl Torbjörn Bäckström BRD	Director/Board Member	76	01/17/01
Maria-Teresa Essen-Möller BRD	Director/Board Member	54	01/09/01
Mark Atkinson BRD	Director/Board Member	63	15/18/15
Karin Rosen BRD	Director/Board Member	57	10/23/10

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	2,741,630	0	0	63.20 %
Stock B	1	92,206,366	60,009,544 ( 65.08 %)	0

Name	Equities	%	Valuation
Bertil Lindkvist 7.952 %	7,700,000	7.952 %	8 M kr
Anders Essen-Möller 3.054 %	2,957,040	3.054 %	3 M kr
Maria-Teresa Essen-Möller 0.9956 %	963,998	0.9956 %	1 M kr
Konstruktions o Försäljningsaktiebolaget KFAB 0.9359 %	906,250	0.9359 %	997 827 kr
Moller Jon Essen 0.4162 %	402,987	0.4162 %	443 709 kr
Moller Martin Essen 0.3083 %	298,513	0.3083 %	328 678 kr
Erika Hillborg 0.2722 %	263,537	0.2722 %	290 167 kr
Ulf Hannelius 0.2453 %	237,500	0.2453 %	261 499 kr
My Essenshaw 0.1869 %	181,002	0.1869 %	199 292 kr
Anna Styrud 0.1420 %	137,499	0.1420 %	151 393 kr

Name	Equities	%	Valuation
Anders Essen-Möller 21.76 %	556,223	21.76 %	612 429 kr
Moller Martin Essen 15.65 %	400,000	15.65 %	440 420 kr
My Essenshaw 15.65 %	400,000	15.65 %	440 420 kr
Moller Jon Essen 15.65 %	400,000	15.65 %	440 420 kr
Erika Hillborg 15.65 %	400,000	15.65 %	440 420 kr
Maria-Teresa Essen-Möller 15.65 %	400,000	15.65 %	440 420 kr

Name	Equities	%	Valuation
Evli Fund Management Co. Ltd. -	3,000	-	685 kr

Diamyd Medical AB

Kungsgatan 29

111 56, Stockholm

+46 86 61 00 26

http://www.diamyd.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
DIAMYD MEDICAL AB	+109.13%	133M
VERTEX PHARMACEUTICALS INCORPORATED	+16.42%	122B
REGENERON PHARMACEUTICALS, INC.	+19.02%	113B
ARGENX SE	+3.14%	22.66B
BIONTECH SE	-16.20%	21.34B
WUXI APPTEC CO., LTD.	-39.57%	16.92B
BEIGENE, LTD.	-11.63%	16.68B
GENMAB A/S	-16.15%	16.61B
NEUROCRINE BIOSCIENCES, INC.	+2.68%	13.62B
SAREPTA THERAPEUTICS, INC.	+21.16%	11.04B

Bio Therapeutic Drugs